156 related articles for article (PubMed ID: 33276182)
1. Therapeutic potential of p53 reactivation in cervical cancer.
Zhao X; Sun W; Ren Y; Lu Z
Crit Rev Oncol Hematol; 2021 Jan; 157():103182. PubMed ID: 33276182
[TBL] [Abstract][Full Text] [Related]
2. Crucial role of TSC-22 in preventing the proteasomal degradation of p53 in cervical cancer.
Yoon CH; Rho SB; Kim ST; Kho S; Park J; Jang IS; Woo S; Kim SS; Lee JH; Lee SH
PLoS One; 2012; 7(8):e42006. PubMed ID: 22870275
[TBL] [Abstract][Full Text] [Related]
3. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
4. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis.
Liu K; Xue B; Bai G; Zhang W
Life Sci; 2020 Oct; 259():118277. PubMed ID: 32800832
[TBL] [Abstract][Full Text] [Related]
5. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
Bykov VJ; Wiman KG
Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination of p53 is involved in troglitazone induced apoptosis in cervical cancer cells.
Chen HM; Zhang DG; Wu JX; Pei DS; Zheng JN
Asian Pac J Cancer Prev; 2014; 15(5):2313-8. PubMed ID: 24716976
[TBL] [Abstract][Full Text] [Related]
7. Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.
Dong P; Xiong Y; Hanley SJB; Yue J; Watari H
J Exp Clin Cancer Res; 2017 Oct; 36(1):150. PubMed ID: 29073938
[TBL] [Abstract][Full Text] [Related]
8. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer.
Sun H; Xin J; Lu Z; Wang N; Liu N; Guo Q
Cell Physiol Biochem; 2013; 32(5):1528-40. PubMed ID: 24335178
[TBL] [Abstract][Full Text] [Related]
9. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
10. Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma.
Zhu HQ; Zhang C; Guo ZY; Yang JM; Guo JH; Chen C; Yao QH; Liu F; Zhang QW; Gao FH
Cancer Med; 2019 Sep; 8(11):5313-5326. PubMed ID: 31339234
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
Soufla G; Baritaki S; Sifakis S; Zafiropoulos A; Spandidos DA
Int J Biol Markers; 2005; 20(1):18-27. PubMed ID: 15832769
[TBL] [Abstract][Full Text] [Related]
12. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
13. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
14. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
15. Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway.
Wang J; Wu Y; Li Y; Wang Y; Shen F; Zhou J; Chen Y
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649833
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
17. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
18. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.
Ou WB; Lu M; Eilers G; Li H; Ding J; Meng X; Wu Y; He Q; Sheng Q; Zhou HM; Fletcher JA
Br J Cancer; 2016 Nov; 115(10):1253-1263. PubMed ID: 27736841
[TBL] [Abstract][Full Text] [Related]
20. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
